To appraise the clinical and cost effectiveness of cemiplimab within its marketing authorisation for treating cutaneous squamous cell carcinoma.
Status In progress
Process STA
ID number 1367

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 01 March 2018 - 29 March 2018
Scoping workshop (London) 30 April 2018 (13:00)

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
05 March 2018 In progress, Ref from DH received 05.12.17
05 December 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance